Motif Bio PLC (LON:MTFB)‘s stock had its “buy” rating reaffirmed by FinnCap in a report released on Wednesday. They currently have a GBX 100 ($1.30) target price on the stock. FinnCap’s price target points to a potential upside of 247.83% from the company’s previous close.

Several other analysts have also recently commented on the stock. Northland Securities reissued a “buy” rating and set a GBX 90 ($1.17) price target on shares of Motif Bio PLC in a research note on Tuesday, May 2nd. Beaufort Securities reissued a “speculative buy” rating and set a GBX 110 ($1.43) price target on shares of Motif Bio PLC in a research note on Wednesday, May 3rd.

Shares of Motif Bio PLC (MTFB) opened at 29.00 on Wednesday. The company’s 50-day moving average price is GBX 29.41 and its 200 day moving average price is GBX 29.22. Motif Bio PLC has a one year low of GBX 21.44 and a one year high of GBX 57.00. The company’s market cap is GBX 56.81 million.

ILLEGAL ACTIVITY WARNING: “Motif Bio PLC (LON:MTFB) Stock Rating Reaffirmed by FinnCap” was posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this story on another website, it was stolen and republished in violation of United States & international copyright & trademark legislation. The correct version of this story can be accessed at https://www.thecerbatgem.com/2017/08/11/motif-bio-plc-lonmtfb-stock-rating-reaffirmed-by-finncap.html.

Motif Bio PLC Company Profile

Motif Bio plc is a clinical-stage biopharmaceutical company. The Company is engaged in development of antibiotics, which are designed for treatment of infections caused by multi-drug resistant bacteria. It operates in the development and commercialization of pharmaceutical formulations segment. The Company is focused on development of its product, Iclaprim, for the treatment of the bacterial infections, such as acute bacterial skin and skin structure infections (ABSSSI) and hospital acquired bacterial pneumonia (HABP), including those caused by resistant strains, such as methicillin-resistant Staphylococcus aureus (MRSA) and multi-drug resistant Streptococcus pneumonia (MDRSP).

Receive News & Stock Ratings for Motif Bio PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Motif Bio PLC and related stocks with our FREE daily email newsletter.